Akari Therapeutics Plc - American Depositary Shares — Cash Flow (NASDAQ:AKTX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -16.95 M-18.85 M-21.5 M-16.43 M-12.55 M-10.57 M -10.57 M Cash from investing activities ————382 K0 — Cash from financing activities 25.07 M14.29 M25.29 M7.02 M10.99 M13.17 M 13.17 M Free cash flow -16.95 M-18.85 M-21.5 M-16.43 M-12.55 M-10.57 M -10.57 M

News

Upcoming Stock Splits This Week (March 30 to April 2) – Stay Invested - TipRanks.com

Akari Therapeutics marks one year under CEO Gaslightwala

Akari Therapeutics adds RNA splicing expert to advisory board

Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Antelope Ent Hldgs (NASDAQ:AEHL), Aimei Health Technology (NASDAQ:AFJK)

Akari Therapeutics advances ADC oncology program with novel payload

Akari begins GMP manufacturing of lead ADC program with WuXi XDC

Akari Therapeutics raises $5 million in at-market offering

Akari Therapeutics stock rises on promising pancreatic cancer drug data

Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance

Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript

Akari Therapeutics appoints Kameel Farag as interim CFO

Akari Therapeutics reports promising data for novel ADC payload